Key Takeaways
- Federal cannabis cases 2025 saw a historic drop to 383 cases, a 62% decrease from 2021, attributed to state-level legalization.
- The U.S. Sentencing Commission (USSC) reported cannabis comprised only 2% of total drug trafficking cases compared to other drugs.
- Rescheduling marijuana to Schedule III acknowledges its medical value, yet it still remains federally controlled and regulated.
- Full descheduling is proposed to eliminate cannabis trafficking designation, allowing for better regulation like alcohol without criminal penalties.
- The focus on federal cannabis policy will continue, addressing rescheduling and calls to commute sentences for those still imprisoned for marijuana offenses.
The U.S. Sentencing Commission (USSC) reported just 383 federal marijuana trafficking cases in fiscal year 2025, a 62% drop from FY 2021 and the lowest figure on record. State-level legalization is widely credited for the decline, creating a bigger question: if cannabis has recognized medical value and trafficking cases have nearly vanished, why does it remain on the Controlled Substances Act at all?
There is no alcohol trafficking category in the USSC’s annual report. No federal “beer smuggling” cases. No wine trafficking statistics. That’s not an accident. Alcohol was removed from the criminal code when Prohibition ended, and the government handed regulation over to licensed markets. The numbers coming out of the USSC in 2025 are making a case that cannabis deserves the same treatment.
According to the USSC’s FY 2025 Quick Facts report, federal marijuana trafficking cases dropped to just 383 in fiscal year 2025. That’s down from 471 in FY 2024, 561 in FY 2023, and 995 in FY 2021. The overall decline from FY 2021 to FY 2025 sits at 62%.
For context, in 2013 there were approximately 5,000 federal marijuana prosecutions. In 2015, that number was still close to 3,500. The data tells shows the obvious, state-level legalization is working exactly the way advocates always said it would.
What Does the USSC FY 2025 Report Actually Show?
The USSC tracks all federal sentencing data and publishes annual quick facts sheets broken down by drug type. The FY 2025 data shows that of 66,662 total federal cases, 16,144 involved drug trafficking. Cannabis accounted for just 2% of those drug trafficking cases.
Here is how cannabis compares to other drug types in FY 2025, according to the USSC:
- Methamphetamine: 7,558 cases (47% of drug trafficking)
- Fentanyl and analogues: 3,892 cases (24%)
- Powder cocaine: 3,054 cases (19%)
- Crack cocaine: 472 cases (3%)
- Heroin: 356 cases (2%)
- Marijuana: 383 cases (2%)
Cannabis carries the lowest average sentence of any trafficked drug at 44 months, compared to 105 months for methamphetamine and 81 months for fentanyl. The USSC also notes that 64% of individuals sentenced for marijuana trafficking had little or no prior criminal history, and 80% were U.S. citizens.
Thisd decline in federal marijuana cases tracks almost perfectly with the expansion of state-level legal markets. Colorado and Washington became the first states to legalize recreational cannabis in 2012. As more states followed, federal cases began their steady descent.
How State Legalization Reduced Federal Cannabis Trafficking
The argument for cannabis legalization has always included an economic and public safety component: when adults can buy cannabis legally and safely from a licensed dispensary, the demand for unlicensed, illicit-market product drops. Fewer buyers for illegal cannabis means less illegal trafficking. Less illegal trafficking means fewer federal prosecutions.
The USSC data reinforces this logic in numbers that are hard to dismiss.
State legalization did not just reduce consumption of illegal cannabis. It redirected that consumption into taxed, regulated, tested markets. The result is fewer trafficking cases, fewer arrests, and fewer people cycling through the federal criminal justice system for cannabis-related offenses.
Does Cannabis Rescheduling Under the CSA Acknowledge Medical Value?
The Justice Department recently moved medical cannabis authorized under state programs from Schedule I to Schedule III of the Controlled Substances Act. Schedule I is reserved for substances with no accepted medical use and a high potential for abuse. Schedule III substances are recognized as having accepted medical use and a lower potential for abuse than Schedule I or II drugs.
That reclassification is significant. For decades, the federal government classified cannabis alongside heroin under Schedule I, a designation that made federally funded research extremely difficult and gave prosecutors power to charge cannabis-related offenses as serious crimes.
Moving cannabis to Schedule III is a formal acknowledgment that the old narrative is no longer defensible. The government is now saying, through its own regulatory process, that cannabis has recognized medical value.
FDA-approved cannabinoid drugs already exist, including Epidiolex (cannabidiol) for seizures and Marinol (synthetic THC) for nausea and appetite stimulation. Schedule III reclassification for state-authorized medical cannabis brings federal policy closer to that existing scientific and medical reality.
But rescheduling is not the same as descheduling. And that distinction matters enormously for the industry, for patients, and for the millions of Americans who use cannabis legally under state law.
Why Rescheduling Could Push Some Cannabis Activity Underground
Federal rescheduling under the CSA, while a meaningful step, also introduces complications that could unintentionally push certain cannabis activity away from regulated markets.
Under Schedule III, cannabis remains a controlled substance subject to DEA oversight, FDA regulatory authority, and federal enforcement mechanisms. For the legal cannabis industry, which already operates in a fractured patchwork of state laws, adding a new layer of federal compliance requirements could raise costs, create barriers for smaller operators, and slow down state-licensed businesses that have already invested heavily in compliance infrastructure.
There is also a real question about what Schedule III means for adult-use recreational cannabis. The rescheduling action taken by the DOJ focused specifically on medical cannabis authorized under state programs. Recreational cannabis remains in a legally ambiguous position. That gap could incentivize some consumers and sellers to operate outside of licensed, regulated channels if the compliance burden of the legal market becomes too high relative to its benefits.
In other words, if the regulatory framework becomes complex enough, some people will find ways around it. That is not speculation. It is the consistent lesson from prohibition-era history and from observations of how over-taxed or over-regulated legal cannabis markets have performed in states like Michigan, where a 24% wholesale tax introduced in 2026 generated far less revenue than projected while legal sales dropped.
Rescheduling solves some problems. It does not solve the structural one.
The Case for Removing Cannabis from the CSA Entirely
Look at the USSC’s annual report and try to find the alcohol trafficking data. You will not find it. There is no federal category for beer or wine smuggling. Alcohol is regulated by the Alcohol and Tobacco Tax and Trade Bureau (TTB), sold through licensed retailers, taxed, and age-restricted. The criminal justice system is not the primary mechanism for alcohol control.
Cannabis could and arguably should work the same way.
Full descheduling, removing cannabis entirely from the Controlled Substances Act, would accomplish several things simultaneously. It would eliminate the federal “trafficking” designation for cannabis entirely, just as removing alcohol from prohibition eliminated alcohol smuggling as a federal crime category. State-licensed businesses could finally access banking services, take standard federal tax deductions, and operate with legal certainty.
Furthermore, researchers would be able to study cannabis without the extraordinary federal barriers that currently exist. And it would end the paradox of a substance being prosecuted as a trafficked drug in federal court while being sold legally in a dispensary down the street.
Descheduling would not mean no regulation. It would mean the right kind of regulation. Think of the tobacco and alcohol model: age restrictions, licensing requirements, advertising rules, and tax structures, without the criminal justice apparatus that has cost billions of dollars and produced declining results for decades.
The USSC data makes clear that federal enforcement of cannabis trafficking is already a marginal activity. The 383 cases in FY 2025 represent a system still spending resources on a problem that state markets have largely solved on their own.
What Comes Next for Federal Cannabis Policy?
The immediate horizon includes the outcome of pending administrative hearings on cannabis rescheduling under the CSA, ongoing pressure from a coalition of lawmakers urging President Trump to commute sentences for people still serving federal time for marijuana, and the larger trajectory of state legalization, which continues to expand.
What that means for future USSC data is worth watching. If rescheduling brings tighter federal oversight without corresponding descheduling, and if some state-legal markets continue to struggle with overtaxation or regulatory burden, it is possible that some illicit activity could persist in the gaps. The declining trajectory of federal cannabis trafficking cases is encouraging. But the goal should be a policy environment where the concept of federal cannabis trafficking becomes as obsolete as federal alcohol smuggling.
That goal is not radical. It is simply the logical extension of where the data is already pointing.
Frequently Asked Questions
According to the U.S. Sentencing Commission (USSC) FY 2025 Quick Facts report, there were 383 federal marijuana trafficking cases in fiscal year 2025. That represents a 62% decline from fiscal year 2021, when 995 cases were recorded.
Federal marijuana trafficking cases have declined as more U.S. states have legalized cannabis for medical and recreational use. State-licensed markets give consumers legal access to regulated cannabis, reducing demand for black-market product. Shifting federal enforcement priorities have also played a role, with agencies increasingly focused on harder drugs like fentanyl and methamphetamine.
Yes, this is a legitimate concern. If rescheduling introduces complex federal compliance requirements, it could raise costs for state-licensed operators and create barriers that make illicit markets more attractive by comparison. Overtaxed or over-regulated state markets have already shown this dynamic, with legal sales declining in some states when the cost burden became too high.
Full descheduling would eliminate the federal “trafficking” designation for cannabis entirely, similar to how ending alcohol Prohibition eliminated federal alcohol smuggling charges. It would allow cannabis businesses to access banking, take normal tax deductions, and operate with legal certainty. State governments could continue to regulate cannabis through licensing, age restrictions, and taxation without the criminal justice system serving as the primary enforcement mechanism.
A coalition of Democratic members of the U.S. House and Senate have called on President Trump to commute the sentences of individuals still serving federal time for marijuana-related offenses. This push has intensified alongside the DOJ’s rescheduling action, with lawmakers arguing that keeping people imprisoned for conduct now recognized as having medical value, or that is fully legal under dozens of state laws, is difficult to justify.
